Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors

References

• Hemophilia A. Genetic and Rare Diseases Information Center (GARD) – an NCATS Program [Internet]. [cited 2021 Jun 17]. Available from: https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a
   Google Scholar
• Hemophilia A. [Internet]. National Hemophilia Foundation. [cited 2021 Jun 17]. Available from: https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a.
   Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. 3rd ed. Haemophilia. 2020;26:1–158.
   PubMed Web of Science ®Google Scholar
• Research C for DE and FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. FDA [Internet]. 2019. [cited 2021 Oct 13]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii.
   Google Scholar
• Research C for DE and FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. FDA [Internet]. 2019. [cited 2021 Oct 13]; Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors.
   Google Scholar
• Croteau SE, Cheng D, Cohen AJ, et al. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019;25(4):668–675.
   PubMed Web of Science ®Google Scholar
• Zhou Z-Y, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia a in the United States. J Med Econ. 2015;18(6):457–465.
   PubMed Web of Science ®Google Scholar
• Shrestha A, Eldar-Lissai A, Hou N, et al. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia. 2017;23(4):e267–e275.
   PubMed Web of Science ®Google Scholar
• McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020;26(4):631–636.
   PubMed Web of Science ®Google Scholar
• Barg AA, Budnik I, Avishai E, et al. Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring. Haemophilia. 2021;27(3):383–391.
   PubMed Web of Science ®Google Scholar
• Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-World data on bleeding patterns of hemophilia a patients treated with emicizumab. JCM. 2021;10(19):4303.
   Web of Science ®Google Scholar
• Vagrecha A, Stanco J, Ulus D, et al. Real-world experience using emicizumab prophylaxis for hemophilia a: single-center experience. Blood. 2020;136(Supplement 1):36–36.
   PubMed Web of Science ®Google Scholar
• Mahajerin A, Khairnar R, Meyer CS, et al. Real-world persistence with and adherence to emicizumab prophylaxis in persons with hemophilia a: a secondary claims database analysis. Blood. 2020;136(Supplement 1):13–13.
   Web of Science ®Google Scholar
• Samelson-Jones BJ, Guelcher C, Kuhn J, et al. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A. Haemophilia. 2021;27(4):591–598.
   PubMed Web of Science ®Google Scholar
• Misgav M, Brutman-Barazani T, Budnik I, et al. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data. Haemophilia. 2021;27(2):253–260.
   PubMed Web of Science ®Google Scholar
• Warren BB, Chan A, Manco‐Johnson M, et al. Emicizumab initiation and bleeding outcomes in people with hemophilia a with and without inhibitors: a single‐center report. Res Pract Thromb Haemost. 2021;5(5):e12571.
   PubMed Web of Science ®Google Scholar
• Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia a with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137(16):2231–2242.
   PubMed Web of Science ®Google Scholar
• Skinner MW, Négrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia a without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021;27(5):854–865.
   PubMed Web of Science ®Google Scholar
• Croteau SE, Cook K, Sheikh L, et al. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. J Manag Care Spec Pharm. 2021;27(3):316–326.
   Google Scholar
• IBM MarketScan Research Databases for Life Sciences Researchers. 2021.
   Google Scholar
• Thornburg CD, Adamski K, Cook K, et al. Health care costs and resource utilization among commercially insured adult patients with hemophilia a managed with FVIII prophylaxis in the United States. J Manag Care Spec Pharm. 2022;28(4):449–460.
   PubMed Web of Science ®Google Scholar
• Moynihan R, Sanders S, Michaleff ZA, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021;11(3):e045343.
   PubMed Web of Science ®Google Scholar
• Caplan EO, Patel AM, DeClue RW, et al. Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age. J Comp Eff Res. 2021;10(15):1121–1131.
   PubMed Web of Science ®Google Scholar
• Lyons J, Desai V, Xu Y, et al. Development and validation of an algorithm for identifying patients with hemophilia a in an administrative claims database. Value Health. 2018;21(9):1098–1103.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017;377(9):809–818.
   PubMed Web of Science ®Google Scholar
• Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia a with inhibitors. Blood. 2019;134(24):2127–2138.
   PubMed Web of Science ®Google Scholar
• Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295–e305.
   PubMed Web of Science ®Google Scholar